Nirmala Bhoo Pathy: Breaking down harmful stereotypes with Cheng-Har Yip

Nirmala Bhoo Pathy shared a post on LinkedIn:

“During our live session on BFM 89.9 – The Business Station today, Prof. Cheng-Har Yip and I unpacked our report from the Lancet Commission on Women, Power, and Cancer for Malaysians.

We dove into challenging and uncomfortable topics like cultural norms, sexual harassment, and gender discrimination. Apart from exploring how these barriers can delay cancer diagnoses and limit treatment access for women, we also illustrated using our own stories how these issues extend into the cancer workforce.

But our discussion wasn’t just about identifying the problems, it was also about breaking down harmful stereotypes.

In a world where men are often celebrated as heroes for their achievements and women are praised as martyrs for their endurance, it’s time to challenge these limiting narratives.

As part of the Lancet Commission, we’re dedicated to reshaping how women’s strength and agency are recognized, ensuring they’re celebrated in all aspects of life, not just in times of suffering.

Listen in to our conversation.”

Source: Nirmala Bhoo Pathy/LinkedIn

More posts by Nirmala Bhoo Pathy on oncodaily.com

Nirmala Bhoo-Pathy is a Professor of Epidemiology in the Department of Social and Preventive Medicine, Faculty of Medicine, University Malaya, and practices as a public health physician at the University Malaya Medical Centre, Malaysia.

She is also a visiting scholar at Queen’s University Belfast, United Kingdom since 2014. Dr Bhoo Pathy’s career is focused on optimizing life after cancer in resource-limited settings through research and advocacy.

Cheng-Har Yip is a prominent breast surgeon with a specific focus on breast cancer surgery and public health interventions. She is the former President of the Asia-Pacific Organization for Cancer Prevention (APOCP) and has been a key figure in implementing breast cancer screening programs in Malaysia.

Her research centers on optimizing early detection methods for breast cancer and improving treatment accessibility in low- and middle-income countries.